Identification of novel small-molecule inhibitors of α-methylacyl-CoA racemase (AMACR; P504S) and structure-activity relationships

Yoana Petrova, Katty Wadda, Amit Nathubhai, Maksims Jevglevskis, Paul Mitchell, Tony James, Michael Threadgill, Tim Woodman, Matthew Lloyd

Research output: Contribution to journalArticle

Abstract

α-Methylacyl-CoA racemase (AMACR; P504S; EC 5.1.99.4) catalyses epimerization of 2-methylacyl-CoAs and is important for the degradation of branched-chain fatty acids and the pharmacological activation of ibuprofen and related drugs. It is also a novel drug target for prostate and other cancers. However, development of AMACR as a drug target has been hampered by the difficulties in assaying enzyme activity. Consequently, reported inhibitors have been rationally designed acyl-CoA esters, which are delivered as their carboxylate prodrugs. The novel colorimetric assay for AMACR based on the elimination of 2,4-dinitrophenolate was developed for high-throughput screening and 20,387 ‘drug-like compounds’ were screened, with a throughput of 768 compounds assayed per day. Pyrazoloquinolines and pyrazolopyrimidines were identified as novel scaffolds and investigated as AMACR inhibitors. The most potent inhibitors have IC 50 values of ~2 µM. The pyrazoloquinoline inhibitor 10a displayed uncompetitive inhibition, whilst 10j displayed mixed competitive inhibition. The pyrazolopyrimidine inhibitor 11k displayed uncompetitive inhibition. This is the first report of the identification of specific drug-like small-molecule AMACR inhibitors by high-throughput screening. Pyrazoloquinolines and pyrazolopyrimidines may also be useful as inhibitors of other CoA-utilizing enzymes.

Original languageEnglish
Article number103264
JournalBioorganic Chemistry
Volume92
Early online date7 Sep 2019
DOIs
Publication statusE-pub ahead of print - 7 Sep 2019

Keywords

  • Branched-chain fatty acids
  • High-throughput screening
  • Ibuprofen metabolism
  • Mixed competitive inhibition
  • Prostate cancer
  • Structure-activity relationships
  • Uncompetitive inhibition
  • α-Methylacyl-CoA racemase (AMACR P504S)

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Drug Discovery
  • Organic Chemistry

Cite this

Identification of novel small-molecule inhibitors of α-methylacyl-CoA racemase (AMACR; P504S) and structure-activity relationships. / Petrova, Yoana; Wadda, Katty; Nathubhai, Amit; Jevglevskis, Maksims; Mitchell, Paul; James, Tony; Threadgill, Michael; Woodman, Tim; Lloyd, Matthew.

In: Bioorganic Chemistry, Vol. 92, 103264, 01.11.2019.

Research output: Contribution to journalArticle

@article{50580effdf1646648abe1943a5de8510,
title = "Identification of novel small-molecule inhibitors of α-methylacyl-CoA racemase (AMACR; P504S) and structure-activity relationships",
abstract = "α-Methylacyl-CoA racemase (AMACR; P504S; EC 5.1.99.4) catalyses epimerization of 2-methylacyl-CoAs and is important for the degradation of branched-chain fatty acids and the pharmacological activation of ibuprofen and related drugs. It is also a novel drug target for prostate and other cancers. However, development of AMACR as a drug target has been hampered by the difficulties in assaying enzyme activity. Consequently, reported inhibitors have been rationally designed acyl-CoA esters, which are delivered as their carboxylate prodrugs. The novel colorimetric assay for AMACR based on the elimination of 2,4-dinitrophenolate was developed for high-throughput screening and 20,387 ‘drug-like compounds’ were screened, with a throughput of 768 compounds assayed per day. Pyrazoloquinolines and pyrazolopyrimidines were identified as novel scaffolds and investigated as AMACR inhibitors. The most potent inhibitors have IC 50 values of ~2 µM. The pyrazoloquinoline inhibitor 10a displayed uncompetitive inhibition, whilst 10j displayed mixed competitive inhibition. The pyrazolopyrimidine inhibitor 11k displayed uncompetitive inhibition. This is the first report of the identification of specific drug-like small-molecule AMACR inhibitors by high-throughput screening. Pyrazoloquinolines and pyrazolopyrimidines may also be useful as inhibitors of other CoA-utilizing enzymes.",
keywords = "Branched-chain fatty acids, High-throughput screening, Ibuprofen metabolism, Mixed competitive inhibition, Prostate cancer, Structure-activity relationships, Uncompetitive inhibition, α-Methylacyl-CoA racemase (AMACR P504S)",
author = "Yoana Petrova and Katty Wadda and Amit Nathubhai and Maksims Jevglevskis and Paul Mitchell and Tony James and Michael Threadgill and Tim Woodman and Matthew Lloyd",
year = "2019",
month = "9",
day = "7",
doi = "10.1016/j.bioorg.2019.103264",
language = "English",
volume = "92",
journal = "Bioorganic Chemistry",
issn = "0045-2068",
publisher = "Elsevier Academic Press Inc",

}

TY - JOUR

T1 - Identification of novel small-molecule inhibitors of α-methylacyl-CoA racemase (AMACR; P504S) and structure-activity relationships

AU - Petrova, Yoana

AU - Wadda, Katty

AU - Nathubhai, Amit

AU - Jevglevskis, Maksims

AU - Mitchell, Paul

AU - James, Tony

AU - Threadgill, Michael

AU - Woodman, Tim

AU - Lloyd, Matthew

PY - 2019/9/7

Y1 - 2019/9/7

N2 - α-Methylacyl-CoA racemase (AMACR; P504S; EC 5.1.99.4) catalyses epimerization of 2-methylacyl-CoAs and is important for the degradation of branched-chain fatty acids and the pharmacological activation of ibuprofen and related drugs. It is also a novel drug target for prostate and other cancers. However, development of AMACR as a drug target has been hampered by the difficulties in assaying enzyme activity. Consequently, reported inhibitors have been rationally designed acyl-CoA esters, which are delivered as their carboxylate prodrugs. The novel colorimetric assay for AMACR based on the elimination of 2,4-dinitrophenolate was developed for high-throughput screening and 20,387 ‘drug-like compounds’ were screened, with a throughput of 768 compounds assayed per day. Pyrazoloquinolines and pyrazolopyrimidines were identified as novel scaffolds and investigated as AMACR inhibitors. The most potent inhibitors have IC 50 values of ~2 µM. The pyrazoloquinoline inhibitor 10a displayed uncompetitive inhibition, whilst 10j displayed mixed competitive inhibition. The pyrazolopyrimidine inhibitor 11k displayed uncompetitive inhibition. This is the first report of the identification of specific drug-like small-molecule AMACR inhibitors by high-throughput screening. Pyrazoloquinolines and pyrazolopyrimidines may also be useful as inhibitors of other CoA-utilizing enzymes.

AB - α-Methylacyl-CoA racemase (AMACR; P504S; EC 5.1.99.4) catalyses epimerization of 2-methylacyl-CoAs and is important for the degradation of branched-chain fatty acids and the pharmacological activation of ibuprofen and related drugs. It is also a novel drug target for prostate and other cancers. However, development of AMACR as a drug target has been hampered by the difficulties in assaying enzyme activity. Consequently, reported inhibitors have been rationally designed acyl-CoA esters, which are delivered as their carboxylate prodrugs. The novel colorimetric assay for AMACR based on the elimination of 2,4-dinitrophenolate was developed for high-throughput screening and 20,387 ‘drug-like compounds’ were screened, with a throughput of 768 compounds assayed per day. Pyrazoloquinolines and pyrazolopyrimidines were identified as novel scaffolds and investigated as AMACR inhibitors. The most potent inhibitors have IC 50 values of ~2 µM. The pyrazoloquinoline inhibitor 10a displayed uncompetitive inhibition, whilst 10j displayed mixed competitive inhibition. The pyrazolopyrimidine inhibitor 11k displayed uncompetitive inhibition. This is the first report of the identification of specific drug-like small-molecule AMACR inhibitors by high-throughput screening. Pyrazoloquinolines and pyrazolopyrimidines may also be useful as inhibitors of other CoA-utilizing enzymes.

KW - Branched-chain fatty acids

KW - High-throughput screening

KW - Ibuprofen metabolism

KW - Mixed competitive inhibition

KW - Prostate cancer

KW - Structure-activity relationships

KW - Uncompetitive inhibition

KW - α-Methylacyl-CoA racemase (AMACR P504S)

UR - http://www.scopus.com/inward/record.url?scp=85072258773&partnerID=8YFLogxK

U2 - 10.1016/j.bioorg.2019.103264

DO - 10.1016/j.bioorg.2019.103264

M3 - Article

VL - 92

JO - Bioorganic Chemistry

JF - Bioorganic Chemistry

SN - 0045-2068

M1 - 103264

ER -